ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on May 14, 2024. The filing serves to announce the company's financial results for the quarter ended March 31, 2024, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the attached press release (Exhibit 99.1) and are not explicitly stated in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended March 31, 2024, by reviewing the attached press release (Exhibit 99.1).
- Confirm that the financial data is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting its legal incorporation into other documents.
- Note the reporting date of May 14, 2024, and the signature by Francois Michelon, President and CEO.